In contrast, specific hepatic mTORC1 suppression via folliculin (FLCN) deletion safeguards against NAFLD/NASH by promoting TFE3-mediated lipid clearance and inhibiting de novo lipogenesis through TFE3-induced Insig2 expression [131]. The gene discussed is INSIG2; the disease is metabolic dysfunction-associated steatohepatitis.